Now, we’re using these capabilities to develop purpose-built #miniprotein medicines designed to match the complexity of human disease.

His expertise and leadership are essential as we continue to industrialize our design-build-test process for drug discovery and work to bring #miniprotein medicines to patients across many diseases.

As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates

James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.

Nice article from @xinruw.bsky.social & David Baker @uwproteindesign.bsky.social w/IPI cofounder Timothy Springer and others. They engineered a de novo #miniprotein, #NeoNectin, that could enhance cell attachment & spreading through binding with #integrin α5β1 ➡️

pubmed.ncbi.nlm.nih.gov/40489013/

Our de novo miniproteins are a novel modality, which means that we're writing the playbook for #miniprotein drug development as we go.

Momentum is building, and AI Proteins @aiproteins.bsky.social is ideally positioned to become the premier platform partner for the discovery and development of #denovo #miniprotein therapeutics

In my academic lab, my research group and I had established the first version of a high-throughput #miniprotein design and engineering platform that united artificial intelligence, synthetic biology, and robotics.

YouTube Share your videos with friends, family, and the world

Our founder, President and CSO Chris Bahl @cdbahl.bsky.social went to the Falling Walls Science Summit last week to explain how we make #miniprotein therapeutics with unprecedented ability to control cellular behavior - you can check out the recording 👇
www.youtube.com/live/zB6-iUB...